Altimmune, Inc. filings document a late clinical-stage biopharmaceutical issuer focused on pemvidutide for serious liver diseases, along with the capital structure used to support that development. Its Form 8-K reports cover operating-result announcements, underwriting agreements, registered direct and at-the-market equity programs, pre-funded warrants, common stock warrants and loan agreement amendments.
Altimmune’s proxy and annual meeting materials disclose shareholder voting matters, governance procedures, executive compensation information and amendments to its certificate of incorporation, including authorized-share matters. The filings also identify its common stock as listed on The Nasdaq Global Market under the symbol ALT.
Altimmune, Inc. Chief Medical Officer Christophe Arbet-Engels had 37,500 restricted stock units vest on October 1, 2026, acquiring 37,500 common shares. He surrendered 12,679 common shares to the issuer solely to cover taxes associated with vesting, at a reported $2.76 per share. The reported position following the RSU transaction was 112,500 RSUs.
Altimmune, Inc. Chief Financial Officer Gregory L. Weaver reported vesting of 14,475 restricted stock units and acquisition of 14,475 common shares on October 1, 2026. He surrendered 4,379 shares at $2.76 per share solely to cover taxes associated with RSU vesting. The reported RSU balance after the transaction was 43,425. No Rule 10b5-1 plan is reported.
Altimmune, Inc. Principal Accounting Officer Richard Thomas Menziuso received 84,546 stock options and 36,234 restricted stock units on October 1, 2026. The options have a $2.76 exercise price. Both awards vest over four years, subject to his continued service on applicable vesting dates.
Altimmune, Inc. (ALT) is identified as the issuer in a Form 3 naming Richard Thomas Menziuso as its Principal Accounting Officer.
Altimmune, Inc. appointed Richard Menziuso as Vice President, Global Controller and Principal Accounting Officer, effective September 29, 2026. Chief Financial Officer Gregory Weaver will remain in that role.
Menziuso has 28 years of finance and accounting experience, including 12 years in public accounting. Before joining Altimmune, he was Vice President, Corporate Controller at Centessa Pharmaceuticals from 2021 until its 2026 acquisition by Eli Lilly, and previously held finance and accounting roles at Thermo Fisher Scientific and Axovant Gene Therapies. Altimmune will enter into an indemnification agreement with him in substantially the same form as its agreement with other executive officers.
Altimmune, Inc. (ALT) reported that Chief Commercial Officer Linda M. Richardson had 24,000 Restricted Stock Units convert into 24,000 shares of common stock on September 16, 2026. Of these, 6,826 shares were surrendered to Altimmune solely to cover taxes on the RSU vesting. After this transaction, 72,000 RSUs remain outstanding, vesting over four years with 25% on September 16, 2026 and the balance in equal annual installments over the next three years, subject to continued service.
Altimmune, Inc. President and CEO Jerome Benedict Durso purchased 15,000 shares of Altimmune common stock on 2026-08-13 in a purchase in open market or private transaction at $2.95 per share. Following this transaction, his directly held position increased to 62,500 shares of common stock.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on liver diseases, led by its dual glucagon/GLP-1 agonist pemvidutide for MASH, AUD and ALD. For the quarter ended June 30, 2026, it reported a net loss of $22.8 million and a six‑month net loss of $45.4 million, driven by research and development expenses of $34.8 million and general and administrative expenses of $15.6 million for the first half of 2026.
Liquidity strengthened significantly: total assets were $527.2 million, including $63.1 million of cash, cash equivalents and restricted cash, $263.3 million in short‑term investments and $192.2 million in long‑term investments, supported by a January 2026 registered direct offering and an April 2026 underwritten offering that together generated about $281.4 million in net equity proceeds. Term loan principal outstanding remained at $35.0 million.
Operationally, pemvidutide received FDA Breakthrough Therapy Designation for MASH, a global PERFORMA Phase 3 MASH trial was initiated with a 52‑week readout expected in 2029, a Phase 2 AUD trial met its primary endpoint with positive topline data, and enrollment in the RESTORE Phase 2 ALD trial was completed. Altimmune also plans to relocate its headquarters to Morristown, New Jersey under a five‑year lease with annual rent of approximately $0.3 million.
Altimmune, Inc. reported second quarter 2026 results and a business update centered on its lead candidate pemvidutide for serious liver diseases. The company highlighted initiation of the global PERFORMA Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), positive topline Phase 2 data in alcohol use disorder (AUD), and completion of enrollment in the RESTORE Phase 2 trial in alcohol-associated liver disease (ALD). Pemvidutide holds FDA Fast Track designations for MASH and AUD and Breakthrough Therapy Designation for MASH.
As of June 30, 2026, Altimmune held $519 million in cash, cash equivalents and investments, providing substantial funding for ongoing trials. Total assets were about $527.2 million and stockholders’ equity about $474.2 million. For the quarter, Altimmune generated no revenue and recorded a net loss of $22.8 million, with research and development expense of $18.7 million and general and administrative expense of $7.6 million$45.4 million. Weighted-average basic and diluted shares outstanding for the quarter were 185.4 million, reflecting a significant increase in the share count compared with the prior year.
Altimmune, Inc. reported that Chief Financial Officer Gregory L. Weaver acquired 1,753 shares of common stock on July 31, 2026 through participation in the company’s 2019 Employee Stock Purchase Plan. The shares were bought at $2.414 per share, equal to 85% of that day’s closing price, for the ESPP period from February 1 to July 31, 2026. Following this plan purchase, Weaver directly holds 39,831 shares of Altimmune common stock.